Interferon alpha-2 clinical trials
Also written Intron A, Interferon Alfa-2b and Intron-A.
How each study uses Interferon alpha-2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Interferon alpha-2 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Jun 1986 · INTRON A · BLA 103132 (FDA, Drugs@FDA)
- European Union
- 9 Mar 2000 · IntronA · EMEA/H/C/000281 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
76 studies that test it; most in 2007 (10)
| Year | Studies |
|---|---|
| 1994 | 2 |
| 1995 | 1 |
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 1 |
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 7 |
| 2006 | 4 |
| 2007 | 10 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 75
National Cancer Institute (NCI) (7) · Roswell Park Cancer Institute (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · M.D. Anderson Cancer Center (4) · Hoffmann-La Roche (4) · Foundation for Liver Research (2) · Kirby Institute (2) · Case Comprehensive Cancer Center (2)
Often tested with
Tested in the same studies.
Ribavirin (9) · poly(I).poly(c12,U) (6) · Celecoxib (6) · Bevacizumab (4) · Peginterferon alfa-2a (4) · Ipilimumab (2) · Cyclophosphamide (2) · Paclitaxel (2)
Related medicines
As reviewed, each with the page that says it.
- One of Interferon Alpha source
- Often written with Interferon-alpha2b in studies. How it relates to Interferon alpha-2 is not confirmed, so neither page counts the other. source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Interferon alpha-2 is the comparator. A study of two new drugs counts under both.
- 1Pembrolizumab · National Cancer Institute (NCI)
- 1Bomedemstat · Merck Sharp & Dohme LLC · next primary completion Jul 2027
Reaching primary completion within a year · 1
Studies that test Interferon alpha-2.
- Apr 2027Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before SurgeryPhase 2 · Roswell Park Cancer Institute
Studies
Open first, then newest update. How each study uses Interferon alpha-2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 83
- To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.RecruitingNot applicableSun Yat-sen UniversityNCT03771677Written as Interferon Alfa-2A
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorActive, not recruitingPhase 3National Cancer Institute (NCI)NCT00569127Written as Recombinant Interferon Alfa-2b
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01274338Written as Recombinant Interferon Alfa-2b
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III MelanomaCompletedPhase 3ECOG-ACRIN Cancer Research GroupNCT00003641Written as interferon alfa-2b
- Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast CancerTerminatedPhase 1/2Roswell Park Cancer InstituteNCT05756166Written as Interferon Alpha-2
- Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk MelanomaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT00539591Written as Recombinant interferon alfa-2b
- Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before SurgeryActive, not recruitingPhase 2Roswell Park Cancer InstituteNCT03899987Written as Recombinant Interferon Alfa-2b
- Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory MelanomaTerminatedPhase 2Roswell Park Cancer InstituteNCT04093323Written as Recombinant Interferon Alfa-2b
- Pegasys® in Patients With Myeloproliferative DiseasesCompletedPhase 2M.D. Anderson Cancer CenterNCT00452023Written as IFN-alpha2a
- Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast CancerCompletedPhase 1Roswell Park Cancer InstituteNCT04081389Written as Recombinant Interferon Alfa-2b
- Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast CancerCompletedEarly Phase 1Roswell Park Cancer InstituteNCT03599453Written as Recombinant Interferon Alfa-2b
- Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell CarcinomaCompletedPhase 1/2Spanish Oncology Genito-Urinary GroupNCT01513187Written as Pazopanib + interferon alpha 2A
- Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the LiverCompletedPhase 2Roswell Park Cancer InstituteNCT03403634Written as Recombinant Interferon Alfa-2b
- Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell LymphomasTerminatedPhase 4Polish Lymphoma Research GroupNCT02323659Written as Interferon Alfa-2b
- A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000754Written as Interferon alfa-2a
- The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's SarcomaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001114Written as Interferon alfa-2b
- A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00008463Written as Interferon alfa-2a
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCVCompletedPhase 3Foundation for Liver ResearchNCT00381953Written as Interferon alfa-2a
- Adoptive T Cell Therapy in Patients With Recurrent Ovarian CancerStatus unknownPhase 1/2Leiden University Medical CenterNCT04072263Written as Interferon Alfa 2A
- Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bCompletedPhase 1Yana NajjarNCT02339324Written as Pembrolizumab and high dose interferon alfa-2b (HDI)
See all 83 studies that test Interferon alpha-2 →
Given beside what is tested · 37 — Interferon alpha-2 is usual care or a partner of the new treatment
- Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian CancerNot yet recruitingPhase 2Kalinski, Pawel, MD, PhDNCT07634094Written as Bioferon
- Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)CompletedPhase 2EIT Pharma, Inc.NCT02430194Written as Pegylated interferon-alfa-2a
- Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01708941Written as Recombinant Interferon Alfa-2b
- Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02107365Written as Pegylated Interferon alpha-2a
- Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer PatientsTerminatedPhase 1/2Roswell Park Cancer InstituteNCT04379518Written as Recombinant Interferon Alfa-2b
- A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B PatientsCompletedPhase 2Shanghai HEP Pharmaceutical Co., Ltd.NCT05244057Written as Pegylated Interferon alfa 2a
- Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01180790Written as Pegylated Interferon alpha-2a
- Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C InfectionCompletedPhase 2TaiGen Biotechnology Co., Ltd.NCT02340962Written as Interferon Alfa-2a
- Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant MelanomaCompletedPhase 3National Cancer Institute, NaplesNCT01359956Written as Interferon Alfa-2b
- SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerCompletedPhase 1/2BriaCell Therapeutics CorporationNCT03066947Written as Interferon-alpha-2b
- Biochemotherapy With Temozolomide for Metastatic MelanomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT00505635Written as Intron-A
- Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)TerminatedPhase 3M.D. Anderson Cancer CenterNCT01821963Written as Pegylated Interferon Alfa 2a
- Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other CancersCompletedPhase 1Case Comprehensive Cancer CenterNCT00498979Written as recombinant interferon alfa-2b
- αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface MalignanciesCompletedPhase 1/2David BartlettNCT02151448Written as Interferon Alfa-2b
- A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02174172Written as Interferon alfa-2b
- Systemic Therapy With Interferon, Interleukin-2 and BRAF InhibitorCompletedPhase 1M.D. Anderson Cancer CenterNCT01603212Written as Interferon Alpha-2b
- Sequential Therapy in Metastatic Renal Cell CarinomaCompletedPhase 2Central European Society for Anticancer Drug ResearchNCT01731158Written as Avastin in combination with Roferon-A
- Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or MyelomaTerminatedPhase 1The Cleveland ClinicNCT00311558Written as recombinant interferon alfa-2b
- Dose Ranging of GSK2336805 in Combination TherapyCompletedPhase 2GlaxoSmithKlineNCT01648140Written as Pegylated interferon alpha-2a
- Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis CCompletedPhase 4Markus Peck-RadosavljevicNCT01925183Written as Pegylated interferon alpha-2a
Showing 20 of 37.
As the comparator · 16 — what is tested is compared with Interferon alpha-2
- Thermosensitive Gel Nasal Spray With Exosomes, Azelastine, and Interferon for Acute Phase of Chronic SinusitisNot yet recruitingEarly Phase 1The First Affiliated Hospital of Xinxiang Medical CollegeNCT07635459Written as Azelastine and Interferon alpha-2b
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02506153Written as Recombinant Interferon Alfa-2b
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT06079879Written as Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b
- The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by SurgeryTerminatedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT03178123Written as high-dose recombinant interferon a-2B
- Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)TerminatedPhase 2/3Merck Sharp & Dohme LLCNCT03547154Written as Interferon alfa-2b
- Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT03537274Written as Interferon Alfa-2B
- 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALTWithdrawnNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT02454764Written as Tenofovir + Interferon alpha 2b
- Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIBCompletedPhase 3University Hospital TuebingenNCT00204529Written as interferon-alpha-2a
- Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedPhase 2Novartis PharmaceuticalsNCT00719264Written as interferon alfa-2a
- Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic MelanomaTerminatedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT00613509Written as Intron A, Interferon alpha -2b
- Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma PatientsStatus unknownPhase 2/3Laboratorio Pablo Cassará S.R.L.NCT01729663Written as interferon alpha 2b
- Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney CancerStatus unknownPhase 2University of AarhusNCT01274273Written as Interferon Alfa-2b
- Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell CarcinomaCompletedPhase 2Centre Leon BerardNCT00619268Written as Interferon alpha-2a
- A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis CCompletedPhase 1/2Digna Biotech S.L.NCT01121731Written as Interferon α-2b (INTRON® A)
- To Study the Efficacy and Safety of Renessans in Chronic HCV PatientsStatus unknownPhase 3MTI Medical Private Limited, PakistanNCT01463592Written as Interferon Alfa-2b AND RIBAVIRIN
- PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)CompletedPhase 3University Hospital, BordeauxNCT00221702Written as intron A
Codes
What other systems call Interferon alpha-2 · ClinicalTrials.gg INT006658
- MeSH (NLM) D000077190Interferon alpha-2Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 43K1W2T1M6INTERFERON ALFA-2BConfirmed FDA, NLM
- RxNorm 5880One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077190 | Interferon alpha-2 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 43K1W2T1M6 | INTERFERON ALFA-2B | Confirmed FDA, NLM |
| RxNorm | 5880 | — | One source FDA |
Also registered as interferon alfa-2a (UNII 47RRR83SK7 · RxNorm 5879).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.